{
    "clinical_study": {
        "@rank": "95841", 
        "arm_group": {
            "arm_group_label": "Cardiac PET", 
            "arm_group_type": "Experimental", 
            "description": "To evaluate methods that could allow the use of two radiotracers(rubidium-82/18F-fluorodeoxyglucose(FDG)and rubidium-82,  that are used in cardiac positron emission tomography(PET)imaging scans to be performed at one time instead of the current method which involves being imaged at separate times, several hours apart."
        }, 
        "brief_summary": {
            "textblock": "Positron emission tomography (PET) scans can be used to evaluate whether parts of the heart\n      muscle are alive but receiving inadequate blood supply.  This study involves the use of two\n      radiotracers that will measure whether heart muscle cell are alive and quantify the blood\n      supply to the heart muscle."
        }, 
        "brief_title": "Initial Human Validation of Simultaneous Dual-Tracer Cardiac PET Imaging", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ischemic Heart Disease", 
            "Myocardial Infarction"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Heart Diseases", 
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "Positron emission tomography (PET) scans can be used to evaluate whether parts of the heart\n      muscle (myocardium) are alive but receiving inadequate blood supply. This information can be\n      helpful in identifying the best course of treatment. This type of study involves the use of\n      two radiotracers: rubidium-82 (to measure blood flow) and 18F-fluorodeoxyglucose or FDG (to\n      measure whether heart muscle cells are alive).  Currently, each of these radiotracers is\n      imaged at separate times, several hours apart.  The purpose of this study is to evaluate\n      methods that could allow the entire study to be performed at one time."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. 18 years of age or older\n\n          2. Patients referred for clinically indicated positron emission tomography (PET)\n             viability assessment with rubidium-82 rest perfusion imaging and\n             18F-fluorodeoxyglucose (FDG) metabolic imaging.\n\n        Exclusion Criteria:\n\n          1. Need for stress perfusion imaging\n\n          2. Claustrophobia which would prevent positron emission tomography (PET) imaging.\n\n          3. Inability to lie flat with arms positioned next to the head for approximately 20\n             minutes.\n\n          4. Clinical instability such as uncontrolled, potentially life threatening arrhythmias\n             or heart failure requiring mechanical support or infusions of inotropic or\n             vasopressor agents.\n\n          5. Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02003456", 
            "org_study_id": "HUM00080193"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cardiac PET", 
                "description": "Study subjects will undergo a Cardiac PET scan that will take approximately 20 minutes to complete.  In addition to standard clinical rubidium-82/18F-fluorodeoxyglucose (FDG) PET imaging, during a separate imaging session, participants will be infused with a second dose of the radio-tracer rubidium-82 during FDG imaging scan that will take an additional 10 to 15 minutes to complete.", 
                "intervention_name": "Cardiac PET w/18F-Fluorodeoxyglucose and rubidium-82", 
                "intervention_type": "Procedure", 
                "other_name": "Positron emission tomography (PET Scan)"
            }, 
            {
                "arm_group_label": "Cardiac PET", 
                "intervention_name": "PET Scan", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Deoxyglucose"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "positron emission tomography", 
            "rubidium", 
            "myocardial perfusion imaging", 
            "viability", 
            "FDG"
        ], 
        "lastchanged_date": "December 5, 2013", 
        "location": {
            "contact": {
                "email": "vlmurthy@med.umich.edu", 
                "last_name": "Venkatesh L. Murthy, M.D.", 
                "phone": "734-936-5387"
            }, 
            "contact_backup": {
                "email": "jmeden@med.umich.edu", 
                "last_name": "Jeffery Meden, C.N.M.T.", 
                "phone": "734-936-5387"
            }, 
            "facility": {
                "address": {
                    "city": "Ann Arbor", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48109"
                }, 
                "name": "University of Michigan Hospital"
            }, 
            "investigator": {
                "last_name": "Venkatesh L. Murthy, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Initial Human Validation of Simultaneous Dual-Tracer Cardiac PET Imaging", 
        "overall_contact": {
            "email": "vlmurthy@med.umich.edu", 
            "last_name": "Venkatesh L. Murthy, M.D.", 
            "phone": "734-936-5387"
        }, 
        "overall_contact_backup": {
            "email": "jmeden@med.umich.edu", 
            "last_name": "Jeffrey Medden, C.N.M.T.", 
            "phone": "734-936-5387"
        }, 
        "overall_official": {
            "affiliation": "University of Michigan Hospital", 
            "last_name": "Venkatesh L. Murthy, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To establish that polar map images from rest rubidium-82 myocardial perfusion imaging performed prior to injection of 18F-fluorodeoxyglucose (FDG) as is routinely performed currently during clinical PET viability studies and rest rubidium-82 myocardial perfusion imaging performed simultaneously with FDG during the second half of an extended FDG imaging session are clinically equivalent.", 
            "measure": "Equivalence of Images from Rest Rubidium-82 Perfusion PET Obtained Separately versus Simultaneously", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02003456"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Michigan", 
            "investigator_full_name": "Venkatesh L. Murthy, M.D., Ph.D.", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To establish that quantitative estimates of global myocardial blood flow at rest determined from rubidium-82 myocardial perfusion imaging performed prior to injection of 18F-fluorodeoxyglucose (FDG) as is routinely performed currently during clinical PET viability studies and rest rubidium-82 myocardial perfusion imaging performed simultaneously with FDG during the second half of an extended FDG imaging session are clinically equivalent.", 
                "measure": "Equivalence of Quantitative Estimates of Global Myocardial Blood Flow using Rubidium-82 Perfusion PET Obtained Separately versus Simultaneously", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "To establish that FDG PET images obtained prior to injection of rubidium-82 and those obtained simultaneously with FDG during the second half of an extended FDG imaging session are clinically equivalent.", 
                "measure": "Equivalence of Images from FDG PET Obtained Separately versus Simultaneously", 
                "safety_issue": "No", 
                "time_frame": "2 Years"
            }
        ], 
        "source": "University of Michigan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Michigan", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}